The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000504314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
31/03/2026
Date registered
Help: Date registered
23/04/2026
Date last updated
Help: Date last updated
2/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
23/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Feasibility of a Diet and Lifestyle Program Guided by Real-Time Glucose Monitoring in Postmenopausal Women at Risk of Type 2 Diabetes
Scientific title
Feasibility of a Diet and Lifestyle Program Guided by Real-Time Glucose Monitoring in Postmenopausal Women at Risk of Type 2 Diabetes
Additional trial identifiers [1] 316929 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
prediabetes 341348 0
hot flashes 341349 0
night sweats 341613 0
Condition category
Condition code
Diet and Nutrition 337420 337420 0 0
Other diet and nutrition disorders
Reproductive Health and Childbirth 337597 337597 0 0
Menstruation and menopause

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
A feasibility clinical trial will be undertaken using a single arm, pre–post intervention design over a six month period. Twenty postmenopausal women at high risk of developing T2D as assessed by the validated Australian T2D Risk Assessment Tool (AUSDRISK) with current VMS who meet the inclusion and exclusion criteria will be recruited to the study.
Following recruitment, baseline anthropometric and cardiovascular health measures will be obtained. Participants will wear a continuous glucose monitor (CGM; Sibionics) for 14 days and download a mobile app to log their food and drink consumption, physical activity, sleep onset, wake time and any VMS during this time. They will have access to the app for the entire six months of the study. The frequency of logs within the app will be recorded and analysed at the end of the study to assess participant adherence. The CGM will be used at four different time points across the six-month study – at baseline (CGM1), Month 2 (CGM2), Month 4 (CGM3) and Month 6 (CGM4).
Participants will apply their baseline CGM (CGM1) and subsequently attend a pathology collection centre for a fasting blood draw and oral glucose tolerance test (OGTT). At the completion of CGM1, participants will be provided with access to the online diet and lifestyle education module within the app.
The education module covers the following seven topics: glucose metabolism (27 articles), nutrition (15 articles), movement (9 articles), sleep (25 articles), stress (4 articles), ageing (3 articles) and menopause (17 articles). The self-paced module takes approximately 8.3 hours to complete and can be done in multiple sittings. Each article provides information that is written for a lay audience and can be read in five minutes or less. Embedded PubMed links allow readers to access the original published articles if they wish. The app records the completion of each article.
Following completion of the education module, participants will be provided with their second (CGM2) and third (CGM3) at Months 2 and 4, respectively. Personalised recommendations to improve glucose metrics will be provided through AI and dietitian generated insights by integrating CGM responses and food logs. The dietician will also offer regular 15-minute synchronous online calls to provide advice tailored to individual dietary preferences and answer specific questions. At the end of CGM2, CGM3 and CGM4, an analytic report is created within the app that summarises an individual’s average 24 hour glucose levels and highlights areas of increased variability that may benefit from targeted diet and/or lifestyle changes.
Anthropometric and cardiovascular health measures will be repeated before participants receive CGM4 at Month 6 and subsequently attend a pathology collection centre for a final fasting blood draw and OGTT. Feasibility of the intervention will be assessed within two weeks of CGM4 completion using validated post study questionnaires.
Intervention code [1] 333642 0
Prevention
Intervention code [2] 333643 0
Lifestyle
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344943 0
recruitment rate
Timepoint [1] 344943 0
study completion
Primary outcome [2] 344944 0
retention rate
Timepoint [2] 344944 0
study completion
Primary outcome [3] 344945 0
adherence
Timepoint [3] 344945 0
study completion
Secondary outcome [1] 459878 0
usability (primary outcome)
Timepoint [1] 459878 0
study completion (post-study survey) within two weeks of completing final CGM
Secondary outcome [2] 459879 0
acceptability, appropriateness and feasibility (composite primary outcome)
Timepoint [2] 459879 0
study completion (post study survey) within two weeks of completing final CGM
Secondary outcome [3] 459880 0
body mass index
Timepoint [3] 459880 0
baseline and 6-months post study commencement
Secondary outcome [4] 460402 0
percent body fat
Timepoint [4] 460402 0
baseline and 6-months post study commencement
Secondary outcome [5] 460403 0
systolic blood pressure
Timepoint [5] 460403 0
baseline and 6-months post study commencement
Secondary outcome [6] 460404 0
diastolic blood pressure
Timepoint [6] 460404 0
baseline and 6-months post study commencement
Secondary outcome [7] 460405 0
LDL-cholesterol
Timepoint [7] 460405 0
baseline and 6-months post study commencement
Secondary outcome [8] 460406 0
triglycerides
Timepoint [8] 460406 0
baseline and 6-months post study commencement
Secondary outcome [9] 460407 0
HbA1c
Timepoint [9] 460407 0
baseline and 6-months post study commencement
Secondary outcome [10] 460408 0
fasting glucose
Timepoint [10] 460408 0
baseline and 6-months post study commencement
Secondary outcome [11] 460409 0
Matsuda index
Timepoint [11] 460409 0
baseline and 6-months post-study commencement
Secondary outcome [12] 460410 0
HOMA-IR
Timepoint [12] 460410 0
baseline and 6-months post study commencement
Secondary outcome [13] 460411 0
hs-CRP
Timepoint [13] 460411 0
baseline and 6-months post study commencement

Eligibility
Key inclusion criteria
Healthy postmenopausal women < 60 years of age living in South Australia following an omnivorous diet, AUSDRISK score greater than or equal to 12, experienced at least one/week of hot flashes or night sweats during the previous two weeks, naive to medications that affect insulin sensitivity within the past three months, willingness to provide fasting blood draw and oral glucose tolerance test at baseline and 6-months, willingness to attend free self service health check (10 minutes) at baseline and 6-months, willingness to complete an online questionnaire at baseline, six-months and post-study, willingness to wear a continuous glucose monitor for 14 days, log the timing of food and drink consumption and vasomotor symptoms (repeated four times across the study), and a compatible smart phone.
Minimum age
41 Years
Maximum age
59 Years
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Surgically-induced menopause, early menopause (onset being less than or equal to 40 years of age), any current or historical diagnosed medical condition associated with metabolic health, current or historical smoker within the past five years, allergy to medical grade adhesives, history of bariatric surgery, current diagnosis of sleep disorders and/or shift work, current diagnosis of severe mental illness, and current or past diagnosis of disordered eating and/or greater than or equal to 15 score on the 12-item Short Form of the Eating Disorder Examination Questionnaire (EDE-QS).

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321525 0
Charities/Societies/Foundations
Name [1] 321525 0
Flinders Foundation
Country [1] 321525 0
Australia
Funding source category [2] 321526 0
University
Name [2] 321526 0
Flinders University
Country [2] 321526 0
Australia
Primary sponsor type
University
Name
Flinders University
Address
Country
Australia
Secondary sponsor category [1] 324434 0
None
Name [1] 324434 0
None
Address [1] 324434 0
Country [1] 324434 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320059 0
Flinders University Human Research Ethics Committee
Ethics committee address [1] 320059 0
Ethics committee country [1] 320059 0
Australia
Date submitted for ethics approval [1] 320059 0
08/04/2026
Approval date [1] 320059 0
26/05/2026
Ethics approval number [1] 320059 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149298 0
Dr Elke Sokoya
Address 149298 0
Flinders University, GPO Box 2100, Adelaide SA 5001
Country 149298 0
Australia
Phone 149298 0
+61 08 8201 3618
Fax 149298 0
Email 149298 0
Contact person for public queries
Name 149299 0
Elke Sokoya
Address 149299 0
Flinders University, GPO Box 2100, Adelaide SA 5001
Country 149299 0
Australia
Phone 149299 0
+61 08 8201 3618
Fax 149299 0
Email 149299 0
Contact person for scientific queries
Name 149300 0
Elke Sokoya
Address 149300 0
Flinders University, GPO Box 2100, Adelaide SA 5001
Country 149300 0
Australia
Phone 149300 0
+61 08 8201 3618
Fax 149300 0
Email 149300 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Studies exploring new research questions
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.